Pharma
Follow
Find
39.4K views | +24 today
Scooped by Andrew Spong
onto Pharma
Scoop.it!

Predicting success for new drugs using Social Media analysis

Predicting success for new drugs using Social Media analysis | Pharma | Scoop.it

Treato's Gideon Mantel writes:

 

Social media can predict the success of a new drug launch much faster than traditional methods. Many pharmaceutical companies try to measure the success of their launch based on weekly script trends. The difference between social media data and data derived from prescriptions is significant: social media data can predict the future, while script data record the past.

 

Social media can also, to some degree, explain events and not just record them, since patient posts are much more nuanced than purchase data, often sharing the why and not just the what.

 

Using older methods, it can take years to understand the result and impact of a new drug launch. Today social media can provide early vital signals in real time.

 

To illustrate this, let’s look at Tecfidera (formerly called BG-12 during clinical trials), a new multiple sclerosis drug that Biogen launched on April 13 [through an examination of the patient voice from billions of patient-written social media posts on over 2,000 health blogs and forums].

 

Interestingly, since the launch of Tecfidera in mid-April, the most talked about MS drug in social media has been Tecfidera, bypassing all other MS medications and growing on a daily basis. We also see significant differences between Tecfidera discussions and that of other MS medications in that 36% of the Tecfidera discussions are on Facebook while for other MS medications only 28% of the discussions are taking place on Facebook (our analysis does not include Twitter).

more...
Art Jones's curator insight, May 31, 2013 7:45 AM

Monitoring social media conversations can predict the success of a new drug or not, more accurately than in the past.

Marie Ennis-O'Connor's curator insight, June 1, 2013 4:44 AM

Interesting.

Pharma
Curating the writing of pharma's digital prescription
Curated by Andrew Spong
Your new post is loading...
Your new post is loading...
Rescooped by Andrew Spong from Patient
Scoop.it!

Healthcare is getting better. Let's talk about what you can do to make it even better, faster.

Healthcare is getting better. Let's talk about what you can do to make it even better, faster. | Pharma | Scoop.it

Click on the link above to contact Andrew Spong, Managing Director, STweM Ltd.

more...
Scooped by Andrew Spong
Scoop.it!

Tablets vs. paper: how the Philippines halved the cost of healthcare delivery

Tablets vs. paper: how the Philippines halved the cost of healthcare delivery | Pharma | Scoop.it

A project in the Philippines has reduced the cost of collecting healthcare information and delivering public health messages to the poorest families by almost half over five years, a university study has found.

 

ACCESS, a non-profit think tank, has trained the government’s community health teams to collect health information on families using tablets, replacing paper forms which they had been using since 2011.

 

The health workers can now use a mobile and web app to summarise the data collected and automatically generate reports. The City Health Office can also directly access the reports online and share them with other government agencies.

Andrew Spong's insight:

A lesson in how effective technology can be in delivering great results from an HEOR perspective when legacy EHR vendors don't get in the way.

more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

Pharma social media: five best practice examples

Pharma social media: five best practice examples | Pharma | Scoop.it

Phil Baumann proposes that pharma companies planning on supporting activities in social environments:

 

Identify clear and specific objectives that lend themselves to social media outletsMatch the social media platform to the brand’s specific objectivesDevelop guidelines and workflows for interactions and engagement opportunitiesEnsure that qualified staff manage all of your social media activitiesWork with vendors who understand customer care and know how to handle all aspects of social media including adverse event identification, correction of misinformation and patient engagement within the unique parameters of each social media platform
Andrew Spong's insight:

Appropriate aims. Adequate preparation. Purposeful participation. Sure-footed execution.

 

It's a shame that more companies don't feel compelled to follow modest, achievable, and productive agendas such as Phil sets out here.

 

At this stage, one can only assume that it is a lack of desire mixed with a fear of career-limiting mistakes.

 

The manifestation of either of those conditions would be a pity, yet the likelihood is that both of them pertain.

 

People working in the pharmaceutical industry are stewards of more than just their own careers. If they're risk averse, it may be better to find another industry.

 

The pharmaceutical industry matters too much for it to be led by the faint-hearted.

 

more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

Industry usage of social media in clinical research

Industry usage of social media in clinical research | Pharma | Scoop.it
The Tufts Center for the Study of Drug Development convened 20 pharmaceutical companies and contract research organizations (CROs) to provide insight into how social media was being used in drug research. Some of the findings highlight the worries that pharmaceutical companies have when dealing with social media in general.
more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

Social entailments: the gulf between patient goals and pharma actions

Social entailments: the gulf between patient goals and pharma actions | Pharma | Scoop.it

Pharma’s participation in digital environments has a price of entry, namely recognising and responding to the necessary consequences of their doing so.

 

Attending to the items described in this post would take any pharma activity in a digital environment some distance towards requiting this debt, although it can never settle it in full.

 

Transactional relationships in digital environments give and take, indefinitely.

 

There is no final reckoning.

 

However, in order to discern where the industry is in debt, and where it may even occasionally be in credit, with regard to patient opinion, pharma need only do one thing:

 

Ask.

more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

FDA: Regulators can't scale to police mobile health apps

FDA: Regulators can't scale to police mobile health apps | Pharma | Scoop.it
A senior advisor to the FDA said the agency couldn't possibly scale up to meet the challenge of policing the hundreds of new apps appearing every month.
more...
Joel Finkle's curator insight, July 7, 6:05 AM

This is somewhat sad -- but perhaps those of us who do submit for review can badge our apps with "FDA Approved!"

Scooped by Andrew Spong
Scoop.it!

Top mobile healthcare apps offer ubiquity and security

Top mobile healthcare apps offer ubiquity and security | Pharma | Scoop.it
Reading into research from Fiberlink Communications, CIOs value mobile healthcare apps that are secure and productive, above all else.
more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

From beyond the pill to beyond the pixel: twelve digital health companies championed by Apple

Apple features 12 digital health products in its new iPhone 5s ad ranging from apps to track your work out to devices to analyze your form.
Andrew Spong's insight:

There have been many ongoing conversations about threats to pharma's visibility in digital environments emerging from outside the industry.

 

As hardware manufacturers align themselves with companies responsible for apps and peripherals compatible with their devices, another challenge to pharma's visibility and relevance in digital spaces has emerged.

 

 

more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

Successful mobile health apps: four determining factors

Successful mobile health apps: four determining factors | Pharma | Scoop.it

Mobile research firm research2guidance surveyed more than 2,000 developers and found some common traits among the successful mobile health apps:

 

Their revenue model is service-based, rather than based on paid downloads. More than a third of so-called successful apps, ranging from image sharing to sophisticated remote monitoring, get their revenue primarily from service sales, research2guidance said.

They integrate with other databases or health tracking devices. Open APIs allow apps to access more data that can enrich their value.

They have a large portfolio. More than one-third of the “successful” developers had published more than 20 mobile health apps, the firm said.

IOS is their No. 1 platform. A whopping three-fourths of successful developers had a preference for iOS over Android.

more...
ChemaCepeda's curator insight, May 20, 2:34 AM

Añadiría otros factores que salieron en #eSaludCyL como la facilidad de uso y la motivación para su utilización a largo plazo

Rowan Norrie's curator insight, May 21, 3:30 AM

Excellent article highlighting key facts about the mobile health sector, with link to free report.

Scooped by Andrew Spong
Scoop.it!

Samsung the pharmaceutical company, and the coming changes in rheumatoid and psoriatic arthritis

Samsung the pharmaceutical company, and the coming changes in rheumatoid and psoriatic arthritis | Pharma | Scoop.it

In 2016, Samsung will be the first consumer technology company to enter the pharmaceutical marketplace with a biosimilar version of Amgen's moderate to severe rheumatoid arthritis and psoriatic arthritis treatment, Enbrel.

 

If this thought doesn’t focus legacy pharmaceutical companies into throwing everything they have into reforming themselves as social business, nothing will. The survival of even the largest companies is far from certain when giants such as Samsung have set their sights upon entering the industry.

 

Samsung doesn’t think like a pharmaceutical company.

 

Pharmaceutical companies better start thinking like Samsung.

more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

Samsung, the pharma company: biopharm investments; first biosimilars in 2016

Samsung, the pharma company: biopharm investments; first biosimilars in 2016 | Pharma | Scoop.it

South Korea’s biggest company is investing at least $2 billion in biopharmaceuticals, including the growing segment of biosimilars, which are cheaper versions of brand-name biotechnology drugs that have lost patent protection.

 

Samsung, with $327 billion annual revenue, aims to become a major force in biotechnology, an industry expected to generate sales of more than $220 billion in five years. With the electronics market reaching saturation, billionaire chairman Lee Kun Hee has been investing in new areas that might shore up growth for the family-controlled company.

 

Samsung plans to sell its first biosimilar version of Amgen Inc. (AMGN)’s arthritis therapy Enbrel in 2016 in Europe and a version of Johnson & Johnson (JNJ)’s Remicade treatment for autoimmune diseases in 2017, according to Ko. A separate unit called Samsung Biologics Co. has contracts to manufacture biologic medicines for branded pharmaceutica

Andrew Spong's insight:

For me, this is the biggest health story of the year so far.

 

With Samsung's dominance in the mobile market and its focus on integrating health into its products, there can be little doubt that the company has the potential to make a huge impression on the future of healthcare.

more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

Corporate Communications should not be implementing pharma's social media

Corporate Communications should not be implementing pharma's social media | Pharma | Scoop.it
Corporate Communications is fine for implementing social media for investor relations but patients and caregivers want someone who can keep it real and speak to them with respect, transparency and honesty.
Andrew Spong's insight:

Aside from corporate reporting, I whole-heartedly agree with Rich on this.

 

Clearly, pretty much the opposite is the case at present, and the longer the status quo is preserved, the harder it will be for the industry to break away from a decision which use and familiarity have legitimated over time, and which is looking less and less viable.

 

Social media sits for the most part in pharma corporate communications because it's the easiest thing to do, not because it's the right thing to do.

more...
Tanja Juslin's curator insight, May 15, 1:13 AM

Challenges seen both when corporate communication is doing what they "technically" know best and when therapy area specialist would know the area best, it's not clear that they can "technically" manage this.

Scooped by Andrew Spong
Scoop.it!

Merck's EHR alliance to improve patient health

Merck's EHR alliance to improve patient health | Pharma | Scoop.it

In one of its first digital health initiatives, Merck has partnered with web-based electronic health record provider Practice Fusion to help doctors track the percentage of their adult patients who are up to date on their vaccines.

more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

PMCPA commissions The EarthWorks to develop an app to simplify the APBI Code of Practice

PMCPA commissions The EarthWorks to develop an app to simplify the APBI Code of Practice | Pharma | Scoop.it

The UK's Code of Practice regulator is turning to digital technology for a strategic communications programme that will see it launch a new app to simplify the ABPI Code next year. 

 

The PMCPA, which administers the Code, will work with Marlow-based agency The Earthworks to create a strategic communications programme that will also include content marketing on the PMCPA's website and through social media channels.  

 

Vicky Bewer, head of communications at the PMCPA, said: “We are excited about the PMCPA becoming more active in the digital space, with The EarthWorks helping us maximise social media and the quality content we already have.”  

 

The PMCPA has often struggled with its online presence, so anything that can raise its digital game will likely be welcomed by its stakeholders.

 

Through the new partnership The Earthworks will be promoting a strong and positive profile for the PMCPA's work in relation to the Code and helping build awareness of, and promote, the benefits of self-regulation to the industry, health professionals, patients and the public.

Andrew Spong's insight:

I'm pleased to see the PMCPA partnering with a trusted and capable service provider to get this important work done.

 

Good news for all stakeholders.

more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

Deal between Google and Novartis will see the development of non-invasive smart lenses

Deal between Google and Novartis will see the development of non-invasive smart lenses | Pharma | Scoop.it

Google[x] and Novartis' eye care division Alcon will create smart lenses that feature "non-invasive sensors, microchips and other miniaturized electronics" and focus on two main areas.

 

The first will provide a way for diabetic patients to keep on top of their glucose levels by measuring the sugar levels in their tear fluid, feeding the data back to a smartphone or tablet. The second solution aims to help restore the eye's natural focus on near objects, restoring clear vision to those who are only farsighted (presbyopia).

 

Andrew Spong's insight:

Non-invasive, all-pervasive sensors in health: #NIAP begins here

more...
rob halkes's curator insight, July 16, 7:11 AM

This certainly is a logical follow up of earlier policy intentions by Mac and Samsung : the health world is changing indeed.

See here and here and here

Scooped by Andrew Spong
Scoop.it!

The pharma Singularity is near

The pharma Singularity is near | Pharma | Scoop.it

The pharma Singularity is near, and on the basis of the evidence that we have to hand, it appears it will be arriving a good deal sooner than 2045.

more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

If patients aren't responding to your digital activity, it's probably because they think it's no good

If patients aren't responding to your digital activity, it's probably because they think it's no good | Pharma | Scoop.it
Patients who are slow to respond to pharma's digital healthcare initiatives are not ignoring you. They just think that your existing services don't meet their needs, or are of poor quality, or both
more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

Digitally Sick is back!

Digitally Sick is back! | Pharma | Scoop.it
Andrew Spong's insight:

A new pod from  the digital pharma podcast Digitally Sick  wherein the resident team of Faisal Ahmed (@cleverpeeps), Alex Butler (@alex__butler), and Andrew Spong (@andrewspong) consider what's new in pharma social media, communications to healthcare professionals, and big data.

more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

Big Tech as the new Big Pharma: reflecting on Facebook's controversial experiment

Big Tech as the new Big Pharma: reflecting on Facebook's controversial experiment | Pharma | Scoop.it
Research in digital media is turning data science into human subjects research.
more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

The top 20 pharma app makers

The top 20 pharma app makers | Pharma | Scoop.it

The medical app market is dominated by the big players, since they have the resources to create the best apps and the financial muscle to push their products in the market.

 

The lion’s share of the medical apps market is occupied by established companies with historically strong brands. Bayer leads the pack with 11.2% market share, followed closely by Merck, Novartis, Pfizer, and Boehringer Ingelheim

more...
Paulo Machado's curator insight, July 9, 8:14 AM

How about a measure of health impact of these apps?  As BioPharma(& other corps) move into health apps shouldn't they be measuring Benefits/Risks like is done with Medicine?

Scooped by Andrew Spong
Scoop.it!

42 percent of pharma companies are increasing spending on patient-oriented comms in 2014

more...
Bettina Gifford's curator insight, July 3, 2:35 PM
Www.hcpmeetings.com.au can let your HCPs know about your programs plus meetings...
Scooped by Andrew Spong
Scoop.it!

Looking beyond patient engagement for pharma and social media

Looking beyond patient engagement for pharma and social media | Pharma | Scoop.it

Mark Senak (@EyeonFDA) writes:

 

"Twitter is the medium for reporting news and at medical meetings there is a lot of news to report, and hence, a good deal to follow.  Reporters, scientists, physicians, patient groups are all commenting and reporting on what they are seeing and hearing that is of interest at meetings and the increase in twitter use at medical meetings from year to year is huge, with particular increases reported for the ASCO and ASH meetings.

 

This is also whypharma web sites (and medical society websties) need to be optimized for mobile,because people aren’t walking around medical meetings using their laptops – they are on their phones."

 

more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

Pharma's role in the digital health landscape

Pharma's role in the digital health landscape | Pharma | Scoop.it
more...
malek's curator insight, May 14, 8:30 AM

The health costs, access and resources are a key driver to seeking solutions to the health dilemma that exists right now and is projected to only get worse.  

Scooped by Andrew Spong
Scoop.it!

Followers of healthcare companies: an infographic

Followers of healthcare companies: an infographic | Pharma | Scoop.it
more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

Surveying the therapeutic areas pharma participates in on facebook, YouTube and Pinterest

Surveying the therapeutic areas pharma participates in on facebook, YouTube and Pinterest | Pharma | Scoop.it

Many companies have created online forums as support networks for patients and their loved ones. Customized online communities can greatly impact patients, but many of these support groups can also be found on mainstream platforms like Facebook.


The article show popular therapeutic areas that are represented on pharma-sponsored Facebook, YouTube and Pinterest sites, according to secondary research conducted by CEI analysts.


In these graphics, the larger the circle, the larger a presence the therapeutic area has on the social media platform. These data suggest that central nervous system (CNS), diabetes and oncology patients have many options for online support. But there are also options for endocrinology, respiratory and immunology patients – to only name a few.

 

Facebook is shown above.

 

YouTube: http://www.cuttingedgeinfo.com/wp/wp-content/uploads/Figure-2-YouTube-TA-presence-JPEG-400x299.jpg

 

Pinterest: http://www.cuttingedgeinfo.com/wp/wp-content/uploads/Figure-3-Pinterest-TA-presence-JPEG-400x300.jpg

 

 

more...
No comment yet.
Scooped by Andrew Spong
Scoop.it!

Pharma's current business model 'does not put the patient at the heart of its decision-making', says KPMG

Pharma's current business model 'does not put the patient at the heart of its decision-making', says KPMG | Pharma | Scoop.it

Pharmaceutical companies need to stop simply paying lip-service to patients and radically alter their business models if they are to meet increasing global demand while improving patient outcomes, says KPMG.

more...
rob halkes's curator insight, April 16, 2:03 AM

Indeed the pharma model needs to be build on an comprehensive view on pharma's role, actions and services in the market. See a draft version to this here:
http://www.healthbusinessconsult.com/blog/customer-focus-in-pharma-22/